Administration of a PPARγ agonist in conjunction with trastuzumab(Herceptin), a humanized monoclonal anti-HER-2/neu antibody used in thetreatment of metastatic and high-risk HER-2/neu+ breast cancer, could alsorepresent a novel combination of targeted therapies. This evidence concerns the gene ERBB2 and breast carcinoma.